| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2017-05-31 |
Baxalta (USA - IL) Mayo Clinic (USA - MN) |
|
|
research - R&D |
Kidney diseases - Renal diseases |
Research agreement |
| 2017-05-31 |
Array BioPharma (USA - CO) Ono Pharmaceutical (Japan) |
binimetinib and encorafenib |
BRAF-mutant melanoma, BRAF-mutant colorectal cancer |
licensing - development - commercialisation |
Cancer - Oncology |
Licensing agreement |
| 2017-05-31 |
MabVax Therapeutics (USA - CA) Memorial Sloan Kettering Cancer (USA - NY) |
novel Chimeric Antigen Receptor (CAR) T-cell therapeutics using antibody targeting sequences derived from MabVax's fully-human antibodies (HuMab-5B1) |
pancreatic cancer, small cell lung cancer, and other solid tumor cancers |
research - R&D |
Cancer - Oncology |
Research agreement |
| 2017-05-31 |
MeiraGTx (USA - NY) |
new premises at the Leiden Bio Science Park |
|
opening of new premises |
Rare diseases - Genetic diseases |
Opening of new premises |
| 2017-05-31 |
Iltoo Pharma (France) Servier (France) |
ILT-101 (low-dose interleukin-2) |
systemic lupus erythematosus (SLE) |
licensing |
Autoimmune diseases |
Licensing agreement |
| 2017-05-30 |
Immunogen (USA - MA) Sanofi (France) |
isatuximab (SAR650984), SAR566658, SAR408701, additional antibody drug conjugate directed to an undisclosed target, SAR428926 |
|
licensing - development - manufacturing - commercialisation |
Cancer - Oncology |
Licensing agreement |
| 2017-05-30 |
Array BioPharma (USA - CO) BMS (USA - NY) |
binimetinib with Opdivo® (nivolumab) and Opdivo® + Yervoy® (ipilimumab |
metastatic colorectal cancer in patients with microsatellite stable tumors |
clinical research |
Cancer - Oncology |
Clinical research agreement |
| 2017-05-30 |
Cambrex (USA - NJ) |
cGMP facility in Karlskoga (Sweden) |
|
opening of new premises |
Technology - Services |
Opening of new premises |
| 2017-05-30 |
Alkermes (Ireland) |
chief medical officer |
|
nomination |
CNS diseases |
Nomination |
| 2017-05-30 |
Orchard Therapeutics (UK) PCT Cell Therapy Services (USA - NJ) |
manufacturing services for OTL-101 |
|
production |
Rare diseases - Genetic diseases - Technology - Services |
Production agreement |
| 2017-05-30 |
Viratherapeutics (Austria) |
chief executive officer |
|
nomination |
Cancer - Oncology |
Nomination |
| 2017-05-24 |
Pierre Fabre laboratories (France) Igenica Biotherapeutics (USA - CA) |
immunotherapies targeting immune checkpoints |
|
product acquisition |
Cancer - Oncology |
Product acquisition |
| 2017-05-24 |
Lysogene (France) Brammer Bio (USA - MA) |
- LYS-GM101 - adeno-associated viral vector serotype rh.10 expressing beta-galactosidase
|
GM1 gangliosidosis |
manufacturing - coproduction |
Rare diseases - Genetic diseases - Technology - Services |
Production agreement |
| 2017-05-23 |
Nabriva Therapeutics (Austria) Nabriva Ireland (Ireland) |
|
|
establishment of a new subsidiary in the EU |
Infectious diseases |
Establishment of a new subsidiary in the EU |
| 2017-05-23 |
Immunogen (USA - MA) Debiopharm (Switzerland) |
IMGN529/DEBIO 1562 |
B-cell malignancies, such as non-Hodgkin lymphomas |
product acquisition |
Cancer - Oncology |
Product acquisition |
| 2017-05-23 |
Bluebird bio (USA - MA) Duke University (USA - NC) Value-Based-Payment-Consortium |
value-based payment reform models for gene therapies and other innovative treatments |
|
collaboration |
|
Collaboration agreement |
| 2017-05-22 |
Nektar Therapeutics (USA - CA) Takeda Pharmaceutical (Japan) |
NKTR-214, with five oncology compounds from Takeda's cancer portfolio |
lymphoma, melanoma, colorectal cancer |
R&D - research |
Cancer - Oncology |
Research agreement |
| 2017-05-22 |
Pieris (Germany) |
|
|
nomination |
Cancer - Oncology |
Nomination |
| 2017-05-22 |
PCI Biotech (Norway) RXi Pharmaceuticals (USA - MA) |
|
|
R&D - research |
Cancer - Oncology |
Collaboration agreement |
| 2017-05-22 |
Atlantic Healthcare (UK) |
non-executive directors |
|
nomination |
Inflammatory diseases - Gastrointestinal diseases |
Nomination |
